News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Capricor Therapeutics, Inc. Enters Into Exclusive License With Cedars-Sinai Medical Center For Exosome-Related IP Portfolio



5/7/2014 9:12:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOS ANGELES, May 6, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced the execution of an Exclusive License Agreement with Cedars-Sinai Medical Center for intellectual property (IP) related to the development of exosomes. Exosome technology may have the potential to form the basis of a next generation therapeutic platform in regenerative medicine. Under the terms of the agreement, Capricor has been granted an exclusive world-wide license, with the right to sublicense, IP related to exosomes originating from cardiosphere-derived cells (CDCs).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES